A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Both
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Trial Information
A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
Inclusion Criteria:
Documented locally advanced or metastatic adenocarcinoma of the stomach or
gastroesophageal junction No prior chemotherapy for locally advanced or metastatic disease
Adequate baseline bone marrow, hepatic and renal function Age >= 18 years At least one
target lesion
Exclusion Criteria:
Active or uncontrolled infections or other serious illnesses or other medical conditions
(eg, hepatitis, HIV, chronic alcohol abuse) Symptomatic brain metastases which are not
stable
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
OSI-904-201
NCT ID:
NCT00073502
Start Date:
October 2003
Completion Date:
October 2003
Related Keywords:
- Gastroesophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Stomach Neoplasms
Name | Location |
|---|---|
| MD Anderson Cancer Center | Houston, Texas 77030-4096 |
| University of Pennsylvania Cancer Center | Philadelphia, Pennsylvania 19104 |
| University of Utah, Huntsman Cancer Institute | Salt Lake City, Utah 84112 |
